এস্তোনিয়া - এস্তোনীয় - Ravimiamet

octapharma (ip) - inimvereplasma proteiinid - infusioonilahus - 70mg 1ml 200ml 10tk; 70mg 1ml 200ml 1tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

csl behring gmbh - viii hüübimisfaktor - süste-/infusioonilahuse pulber ja lahusti - 500rÜ 1tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

csl behring gmbh - viii hüübimisfaktor - süste-/infusioonilahuse pulber ja lahusti - 250rÜ 1tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

csl behring gmbh - viii hüübimisfaktor - süste-/infusioonilahuse pulber ja lahusti - 2000rÜ 1tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

csl behring gmbh - viii hüübimisfaktor - süste-/infusioonilahuse pulber ja lahusti - 1000rÜ 1tk

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

sandoz gmbh - rituksimab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - antineoplastilised ained - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. ainult piiratud andmed on saadaval efektiivsust ja ohutust patsientidel, eelnevalt ravitud monoklonaalsete antikehadega (sealhulgas rituksimabi või patsientidel, tulekindlad, et eelmise rituksimabi pluss kemoteraapiat. vt lõik 5. 1 lisateavet. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituksimabi on näidanud, et vähendada määra progressioon ühise kahju, mida mõõdetakse x-ray ja parandab füüsilist funktsiooni, kui antud koos metotreksaadi. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

wegatred oÜ - taimsed preparaadid - õhukese polümeerikattega tablett - 600mg 60tk; 600mg 30tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

octapharma ab - viii hüübimisfaktor - süstelahuse pulber ja lahusti - 500rÜ 1tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

octapharma ab - viii hüübimisfaktor - süstelahuse pulber ja lahusti - 1000rÜ 1tk

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

takeda manufacturing austria ag - octocog alfa - hemofiilia a. - antihemorraagilised ained - verejooksu ravi ja profülaktika hemofiilia a patsientidel (kaasasündinud faktor viii puudulikkus). advate ei sisalda von willebrand tegur farmakoloogilised tõhus kogused ja ei ole seega näidustatud von willebrand haigus.